Nan Hutchinson | Former Board Member, Cynapsus Therapeutics

Nan is a seasoned well rounded executive who most recently (2014-2016) served as a Board Director for Cynapsus Therapeutics Inc. Cynapsus was a publicly traded specialty central nervous system pharmaceutical company that had been developing a fast- acting, easy- to- use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease. She is a Canadian ex-pat and her experience spans both multi billion dollar global corporations (BMS and J&J) and mid size ($200 million) privately held pharmaceutical companies. She has had global GM responsibility for P&Ls in excess of $2 billion. She has an excellent track record in product launch, characterizing commercial risks and opportunities, partnering and licensing as well as scaling commercial operations. She and has been responsible for the successful worldwide launch of blockbuster products such as Abilify, now a $6.5 billion antipsychotic. She has broad therapeutic experience in CNS, anti-infectives and pain.